Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31505790 | 1.00 | HRH3 (0.46) | HRH3RETOGAKDM4EALDH1A1 | |
| SCHEMBL2562848 | 0.83 | HTR3A (0.47) | HRH3KDM4EALDH1A1 | |
| SCHEMBL29516406 | 0.83 | HTR3A (0.47) | HRH3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL19208199 | 0.81 | HTR3A (0.46) | HRH3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29781926 | 0.81 | HTR3A (0.46) | HRH3KDM4EALDH1A1 | |
| SCHEMBL24504404 | 0.81 | RET (0.45) | RETKDM4EALDH1A1 | |
| SCHEMBL29377204 | 0.80 | UBE2T (0.51) | KDM4EALDH1A1MAPT | |
| SCHEMBL676085 | 0.80 | UBE2T (0.51) | KDM4EALDH1A1MAPT | |
| SCHEMBL12659925 | 0.80 | UBE2T (0.36) | KDM4EALDH1A1MAPT | |
| SCHEMBL9363368 | 0.80 | KDM4E (0.57) | HRH3OGAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338070-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | HRH3 1896/4885RET 1131/4885OGA 1578/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | HRH3 1896/4885RET 1131/4885OGA 1578/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | HRH3 1896/4885RET 1131/4885OGA 1578/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | HRH3 1896/4885RET 1131/4885OGA 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.